Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ocular melanomas : An update].

H Kalirai1, P L Müller2, D Jaehne3

  • 1Liverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, Großbritannien.

Der Pathologe
|October 18, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

ESMO open·2026
Same author

Altered Nuclear Expression of the Deubiquitylase BAP1 Cannot be Used as a Prognostic Marker for Canine Melanoma.

Journal of comparative pathology·2018
Same author

[Primary vitreoretinal lymphoma].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2018
Same author

Electrochemotherapy with bleomycin and cisplatin enhances cytotoxicity in primary and metastatic uveal melanoma cell lines in vitro.

Neoplasma·2018
Same author

[Malignant lymphomas of the eye].

Der Pathologe·2017
Same author

[Morphologic Corneal Changes after Crosslinking for Keratoconus].

Klinische Monatsblatter fur Augenheilkunde·2017
Same journal

[Connective (tissue) pathology: What brings us together!]

Der Pathologe·2022
Same journal

[Giant cell-containing tumors of bone and differential diagnoses].

Der Pathologe·2022
Same journal

[Automation and application of robotics in the pathology laboratory].

Der Pathologe·2022
Same journal

[Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].

Der Pathologe·2022
Same journal

[Artificial intelligence: a solution for the lack of pathologists?]

Der Pathologe·2022
Same journal

[Predictive immunocytochemistry in non-small cell lung carcinoma].

Der Pathologe·2022
See all related articles
This summary is machine-generated.

This review details recent molecular advances in understanding ocular melanomas, focusing on uveal and conjunctival types. These findings improve prognostication and identify new therapeutic targets for eye cancer.

Area of Science:

  • Ophthalmology
  • Oncology
  • Molecular Biology

Background:

  • Ocular melanoma is the most common primary eye cancer in adults.
  • Most ocular melanomas are intraocular (uveal), while a smaller percentage are conjunctival.
  • Uveal and conjunctival melanomas, though originating from melanocytes, are clinically and biologically distinct.

Purpose of the Study:

  • To review recent molecular characterization of uveal and conjunctival melanomas.
  • To discuss how molecular insights can improve prognostication.
  • To identify potential personalized therapeutic strategies for ocular melanoma.

Main Methods:

  • Review of recent scientific literature on ocular melanoma molecular biology.
  • Analysis of molecular advancements in uveal and conjunctival melanoma.
Keywords:
GeneticsImmunotherapyMetastasisTargeted therapyUvea

Related Experiment Videos

  • Discussion of therapeutic target identification.

    • Main Results:

    • Significant progress in understanding the molecular basis of ocular melanoma development and progression.
    • Enhanced prognostication for uveal melanoma based on molecular profiling.
    • Identification of potential molecular targets for disseminated ocular melanoma.

    Conclusions:

    • Molecular characterization is crucial for understanding ocular melanoma subtypes.
    • Advances in molecular biology offer improved diagnostic and prognostic tools.
    • Personalized therapeutic strategies are emerging for ocular melanoma treatment.